Ibnsina Pharma poised to “capitalize on rising demand” -EFG Hermes: Leading frontier and emerging markets investment bank EFG Hermes has initiated coverage on IbnsinaPharma, which it characterizes as “well-positioned to capture Egypt’s rising … demand and continue outperforming the market.” EFG Hermes has a “Buy” on Ibnsina with a target price of EGP 14.00 / share (and room to run to EGP 15.40 depending on the disposition of an antitrust suit the distributor phases). EFG Notes that Ibnsina is Egypt’s fastest growing distributor of pharmagoods and sees its prospects bolstered by an expected 17% five-year compound annual growth rate for the sector as it recovers from shortages following the float of the EGP. The rollout of the Universal Healthcare Act, which could insurance coverage to 100 percent of the population by 2032, would also increase healthcare spending significantly — raising the five-year CAGR to 25 percent. Ibnsina has grown its market share from 9.9% in 2009 to 20.2% in late 2018.